This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provi ...

Wegovy's success, coupled with the ... as Wegovy’s primary competitor. Tirzepatide’s dual agonism mechanism allows for 20% average body weight loss in patients. Recent head-to-head trial ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Wegovy’s success, coupled with the recognition ... quickly emerged as Wegovy’s primary competitor. Tirzepatide’s dual agonism mechanism allows for 20% average body weight loss in patients. Recent head ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the drugs are approved for other chronic conditions ...

However, the real success is reflected in the national ... after stopping The weight-loss drug Zepbound (tirzepatide) has just become the first drug approved by the U.S. Food and Drug ...